Novo plots $191M expansion at Danish plant
Novo Nordisk plans to invest almost 1 billion Danish kroner ($191 million) in a new biologics manufacturing facility in Kalundborg, Denmark that will manufacture biopharmaceuticals such as Factor VIIa, used in Novo's NovoSeven drug for hemophilia, as well as other biologic medicines. Reports
Comments